[PharmaEssentia] Notice of Completion of Patient Enrollment for Phase 3 Trial
PharmaEssentia completed patient enrollment for its Phase 3 trial of P1101 for myelofibrosis.
📋 Article Processing Timeline
- 📰 Published: June 10, 2026 at 09:00
- 🔍 Collected: June 11, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: June 11, 2026 at 09:38 (1h 38m after Collected)
1. Drug Name: Ropeginterferon alfa-2b (P1101)
2. Indication: Pre-fibrotic/Early Primary Myelofibrosis and low/intermediate-1 risk Overt Primary Myelofibrosis.
3. Progress: Completed enrollment of 160 subjects in the Phase 3 clinical trial (HOPE-PMF).
4. Next Step: Continuing the Phase 3 trial, expected completion in 2027.
5. Context: Myelofibrosis is a type of myeloproliferative neoplasm. Existing treatments include JAK2 inhibitors, and this trial explores a new treatment option.
2. Indication: Pre-fibrotic/Early Primary Myelofibrosis and low/intermediate-1 risk Overt Primary Myelofibrosis.
3. Progress: Completed enrollment of 160 subjects in the Phase 3 clinical trial (HOPE-PMF).
4. Next Step: Continuing the Phase 3 trial, expected completion in 2027.
5. Context: Myelofibrosis is a type of myeloproliferative neoplasm. Existing treatments include JAK2 inhibitors, and this trial explores a new treatment option.
FAQ
How many subjects in the trial?
160 subjects.
When will it finish?
Scheduled for 2027.
What is the drug used for?
Treating myelofibrosis.